These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 34463914)

  • 1. Non-IgE-Mediated Drug Hypersensitivity Reactions.
    Joshi SR; Khan DA
    Curr Allergy Asthma Rep; 2021 Aug; 21(7):41. PubMed ID: 34463914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Hypersensitivity Reactions.
    Wilkerson RG
    Immunol Allergy Clin North Am; 2023 Aug; 43(3):473-489. PubMed ID: 37394254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Severe delayed drug hypersensitivity reactions].
    Maniu CM; Buss G; Feldmeyer L; Spertini F; Ribi C
    Rev Med Suisse; 2013 Apr; 9(382):803-4, 806-11. PubMed ID: 23667969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe Drug Hypersensitivity Reactions: Clinical Pattern, Diagnosis, Etiology and Therapeutic Options.
    Paulmann M; Mockenhaupt M
    Curr Pharm Des; 2016; 22(45):6852-6861. PubMed ID: 27779083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Making a diagnosis in severe cutaneous drug hypersensitivity reactions.
    Ardern-Jones MR; Mockenhaupt M
    Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):283-293. PubMed ID: 31247634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management.
    Mustafa SS; Ostrov D; Yerly D
    Curr Allergy Asthma Rep; 2018 Mar; 18(4):26. PubMed ID: 29574562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.
    Pavlos R; Mallal S; Ostrov D; Pompeu Y; Phillips E
    J Allergy Clin Immunol Pract; 2014; 2(1):21-33. PubMed ID: 24565765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulfonamide Hypersensitivity: Fact and Fiction.
    Khan DA; Knowles SR; Shear NH
    J Allergy Clin Immunol Pract; 2019; 7(7):2116-2123. PubMed ID: 31495421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice.
    Peter JG; Lehloenya R; Dlamini S; Risma K; White KD; Konvinse KC; Phillips EJ
    J Allergy Clin Immunol Pract; 2017; 5(3):547-563. PubMed ID: 28483310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations.
    Hsiao YH; Hui RC; Wu T; Chang WC; Hsih MS; Yang CH; Ho HC; Chang YG; Chen MJ; Lin JY; Chen DP; Chang PY; Wu TL; Hung SI; Chung WH
    J Dermatol Sci; 2014 Feb; 73(2):101-9. PubMed ID: 24268988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe delayed skin reactions related to drugs in the paediatric age group: A review of the subject by way of three cases (Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS).
    Belver MT; Michavila A; Bobolea I; Feito M; Bellón T; Quirce S
    Allergol Immunopathol (Madr); 2016; 44(1):83-95. PubMed ID: 26089185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulfonamide Hypersensitivity.
    Chow TG; Khan DA
    Clin Rev Allergy Immunol; 2022 Jun; 62(3):400-412. PubMed ID: 34212341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetics and the potential for predictive tests in adverse drug reactions.
    Pirmohamed M
    Chem Immunol Allergy; 2012; 97():18-31. PubMed ID: 22613851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA and pharmacogenetics of drug hypersensitivity.
    Pavlos R; Mallal S; Phillips E
    Pharmacogenomics; 2012 Aug; 13(11):1285-306. PubMed ID: 22920398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tools to improve the diagnosis and management of T-cell mediated adverse drug reactions.
    Copaescu AM; Ben-Shoshan M; Trubiano JA
    Front Med (Lausanne); 2022; 9():923991. PubMed ID: 36313986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug rash with eosinophilia and systemic symptoms vs toxic epidermal necrolysis: the dilemma of classification.
    Wolf R; Matz H; Marcos B; Orion E
    Clin Dermatol; 2005; 23(3):311-4. PubMed ID: 15896547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of liver injury in drug-induced systemic hypersensitivity reactions.
    Lee T; Lee YS; Yoon SY; Kim S; Bae YJ; Kwon HS; Cho YS; Moon HB; Kim TB
    J Am Acad Dermatol; 2013 Sep; 69(3):407-15. PubMed ID: 23632341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review.
    Cheng CY; Su SC; Chen CH; Chen WL; Deng ST; Chung WH
    J Immunol Res; 2014; 2014():565320. PubMed ID: 24901010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Hypersensitivity Reactions.
    Wilkerson RG
    Emerg Med Clin North Am; 2022 Feb; 40(1):39-55. PubMed ID: 34782090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stevens-Johnson syndrome and toxic epidermal necrolysis due to anticonvulsants share certain clinical and laboratory features with drug-induced hypersensitivity syndrome, despite differences in cutaneous presentations.
    Teraki Y; Shibuya M; Izaki S
    Clin Exp Dermatol; 2010 Oct; 35(7):723-8. PubMed ID: 19874350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.